Week 6

We currently have limited information on whether there are additional risks for people living with type 1 diabetes during the COVID-19 pandemic.

Your responses to this questionnaire will help researchers and medical professionals from around the world to adapt and develop strategies to better respond and provide medical treatment.

The questionnaire will be updated weekly. Please consider completing the questionnaire again every week so that we can track the progress throughout the COVID-19 pandemic.

We value your privacy. At the end of the questionnaire, you will be asked to provide your email address. This is not mandatory and we will never share your email address with anyone.

address. This is not mandatory and we will never share your email address with anyone. Additionally, your answers will always remain anonymous. We will only use your email address (if provided) to keep you updated every time a new weekly survey becomes available. Survey results will feed an interactive dashboard that will be public and updated weekly. Your data will be completely anonymised before public sharing. For any request please contact: t1DCOVID19study@gmail.com
* Do you agree to the above terms? By clicking Yes, you consent that you are willing to answer the questions in this survey
Yes No
Here you can access SurveyMonkey's <u>privacy policy</u> to see how they handle respondent data on our behalf

45-54 55-64 65+
55-64
65+
ompleted or the highest degree you have received?
diabetes?

Do you have any additional medical conditions b	pesides type 1 diabetes?
Yes	
No	
If yes, please specify (optional)	
Did you have any respiratory conditions requiring	g medication over the last 6 months?
Yes	
No No	
Don't remember	
If yes, please specify condition (if known)	
Do you have any of the following complications?	
No complications to report	
Peripheral vascular disease (e.g. impairment of circula	tion in limbs/feet)
Cardiac disease (e.g. coronary heart disease, heart at	tack, heart failure or similar)
Cerebrovascular disease (stroke or similar)	
High blood pressure	
Mild retinopathy (eye disease)	
Severe retinopathy	
Diabetic neuropathy (impairment of nerve function)	
Diabetic nephropathy (albuminuria / renal disease)	
Don't know	
Other (please specify)	
Has the current COVID-19 pandemic affected yo	our access to healthcare?
Yes, my regular diabetes-related appointments have a cancelled	Il been I have spoken to my healthcare provider over the phone via other remote means
No, everything is running as usual	I haven't spoken to my healthcare provider yet
I decided to cancel my regular appointments	
Other (please give details)	

No, and no future appointments are pl	lanned
No, but I plan to have a remote appoir	ntment in the future
Yes	
•	ent with your healthcare provider/endocrinologist since the start of the
pandemic, how useful did you find to No responses needed if you didn't have a	
Extremely useful	Not so useful
Very useful	Not at all useful
Somewhat useful	
If you have had a remote appointm	ent with your healthcare provider/endocrinologist, how was this done
No responses needed if you didn't have a	
Telephone	
Video call e.g. skype/zoom	
Other (please specify)	
How likely are you to consider remo	ote appointments instead of appointments in person after the
	ote appointments instead of appointments in person after the Unlikely
How likely are you to consider remo	
How likely are you to consider remo pandemic? Very likely	Unlikely
How likely are you to consider remo pandemic? Very likely Likely	Unlikely
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely	Unlikely
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely	Unlikely Very unlikely
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affec	Unlikely Very unlikely
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affecting insulin	Unlikely Very unlikely ted your level of access to the following?
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affecting insulin Needles	Unlikely Very unlikely ted your level of access to the following?
How likely are you to consider remonancemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affecting insulin Needles Continuous glucose sensors/flash glucose	Unlikely Very unlikely ted your level of access to the following?
How likely are you to consider reme pandemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affect Insulin Needles Continuous glucose sensors/flash glucose metres	Unlikely Very unlikely ted your level of access to the following?
How likely are you to consider removandemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affect Insulin Needles Continuous glucose sensors/flash glucose metres Testing strips	Unlikely Very unlikely ted your level of access to the following? cose sensors
How likely are you to consider removandemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affect Insulin Needles Continuous glucose sensors/flash glucose metres Testing strips Glucagon	Unlikely Very unlikely ted your level of access to the following? cose sensors
How likely are you to consider remorpandemic? Very likely Likely Neither likely nor unlikely Has the COVID-19 pandemic affect Insulin Needles Continuous glucose sensors/flash glucose metres Testing strips Glucagon Fast-acting carbohydrates to treat hype	Unlikely Very unlikely ted your level of access to the following? cose sensors

* Since the start of the pandemic have you experienced a change in your general glucose control indicated
by any of the following:
Frequency of hypoglycemia (glucose values < 70mg/dl / < 3.9 mmol/L) decreased
Frequency of hypoglycemia (glucose values < 70mg/dl / < 3.9 mmol/L) increased
Frequency of hyperglycemia (glucose values > 180mg/dl / > 10mmol/L) <u>decreased</u>
Frequency of hyperglycemia (glucose values > 180mg/dl / > 10mmol/L) increased
HbA1c increased
HbA1c decreased
No changes observed
I don't know
* If you are using a continuous glucose monitor or flash glucose monitor, have you noticed any of the following since the start of the pandemic?
The time in target range (70-180 mg/dl / 3.9 – 10 mmol/L) of sensor-glucose decreased
The time in target range (70-180 mg/dl / 3.9 – 10 mmol/L) of sensor-glucose increased
Time below target range (< 70mg/dl / < 3.9 mmol/L) of sensor-glucose <u>decreased</u>
Time below target range (< 70mg/dl / < 3.9 mmol/L) of sensor-glucose increased
Time above target range (> 180mg/dl / >10mmol/L) of sensor-glucose decreased
Time above target range (> 180mg/dl / >10mmol/L) of sensor-glucose increased
No changes observed
I don't know
I am not using a continuous glucose monitor or flash glucose monitor
* Have you been tested for COVID-19?
Yes, and it was positive
Yes, and it was negative
○ No

you tested positive for COVID-19 were	you hospitalised?
No	
Yes	
Yes, and have since been discharged from he	ospital
were to the disposition for COVID 10 who	4a.aaaaa.aa.a.a.a.a.a
you tested positive for COVID-19, what I haven't had symptoms	t were your symptoms?
Mild cough	
Severe cough	
Sneezing	
Fever	
Tiredness	
Mild breathing difficulty	
Severe breathing difficulty	
High temperature	
Gastrointestinal symptoms	
uther (please specify)	
пист (рісазе зреспу)	
you have had symptoms, how long did	they last?
I have not had symptoms	6-7 days
1-2 days	7-10 days
3-4 days	More than 10 days
4-5 days	Don't remember
you have at have had COVID 10, how	did it offeet vous gluppes central?
you have or have had COVID-19, how Not at all	Moderately
Slightly	Substantially/Significantly
Somewhat	Cubotalitatiyi Olgi iii Garitiy
Please provide details (optional)	

* Do you feel as though you are at higher risk during t because you have type 1 diabetes?	he COVID-19 pandemic than the average person
Yes	
No No	
Don't know	
Other (please specify)	
* How strongly do you agree with the following statem diabetes management during the COVID-19 panden	
Don't know	Neutral
Strongly agree	Disagree
Agree	Strongly disagree
O 1911	Carango, acagas

They will allow researchers and n	complete this questionnaire. Your responses are extremely valuable to us. medical professionals to adapt during the COVID-19 pandemic. questionnaire again next week so that we can track the progress throughout the COVID-19
Send me a reminder to cor	mplete the questionnaire again next week.
Email Address	
acknowledgement that you Do you consent with you Yes	es affected by GDPR, we are required to request your consent and you authorise us to store your email address. ur personal data being processed as described in the intro page?
No	

Т